New treatment for advanced breast cancer patients approved for NHS use

The National Institute for Health and Care Excellence (NICE) has approved the use of the tablet capivasertib, in combination with fulvestrant, for patients with hormone receptor-positive, HER2-negative breast cancer that has progressed after earlier endocrine treatment. Trials suggest this combination extends the time before the condition progresses by an average of four months compared to fulvestrant alone. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "This new combination treatment offers an additional option for some people whose breast cancer has progressed despite previous hormone therapy, and who may benefit from a targeted approach.

"While it won’t be suitable for everyone, giving patients more time before more intensive therapies are required is an important part of our drive to personalise cancer care and improve quality of life for patients wherever possible.".